comparemela.com

Latest Breaking News On - Sami khella - Page 4 : comparemela.com

Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN

/PRNewswire/ Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform.

United statesSami khellaEugene schneiderAmerican academy of neurologyDrug administrationUniversity of pennsylvania school medicinePrnewswire ionis pharmaceuticals incAmerican academy of neurology annual meetingPenn presbyterian medical centerExchange commissionIonis pharmaceuticalsInternational symposium on amyloidosisIonis pharmaceuticals incAmerican academyAnnual meetingNeuropathy impairment score

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy showed eplontersen met its co-primary endpoints. | March 27, 2023

United kingdomUnited statesEugene schneiderSami khellaPenn presbyterian medical centerDrug administrationIonis pharmaceuticalsColumbia university irving medical centerClinical developmentUniversity of pennsylvania school medicineAmerican academy of neurology annual meetingDepartment of neurologyNeuropathy impairment scoreNorfolk qualityLife questionnaire diabetic neuropathyClinical neurology

Astrazeneca - Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy through 66 weeks

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy showed eplontersen met its co-primary endpoints. | March 27, 2023

United kingdomUnited statesEugene schneiderPatrick barthSami khellaDrug administrationDepartment of neurologyUniversity of pennsylvania school medicinePenn presbyterian medical centerClinical developmentAmerican academy of neurology annual meetingNeuropathy impairment scoreNorfolk qualityLife questionnaire diabetic neuropathyPresbyterian medical centerClinical neurology

Ionis antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting

/PRNewswire/ Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced that multiple presentations highlighting.

C frank bennettSami khellaKemi olugemoArthurk asburyNick vineyPeripheral nerve societyIonis pharmaceuticals incPenn presbyterian medical centerIonis pharmaceuticalsNerve societyAnnual meetingFrank bennettPenn presbyterian medicalAntisense therapiesNeurological diseasesEvaluate eplontersen

vimarsana © 2020. All Rights Reserved.